How US Can Learn From Biosimilar Implementation In EU
This article was originally published in The Pink Sheet Daily
Executive Summary
Differences in payer policies have limited the biosimilar opportunity in some EU nations; IMS report points to examples US should replicate or avoid as biosimilars are introduced domestically.
You may also be interested in...
RAND's 'Best Guess' On Biosimilars Is $54 Bil. In Cost Savings
Another rosy report foresees massive savings over the next decade, but RAND acknowledges that many factors will be the true determinants of spending decreases from biosimilars.
RAND's 'Best Guess' On Biosimilars Is $54 Bil. In Cost Savings
Another rosy report foresees massive savings over the next decade, but RAND acknowledges that many factors will be the true determinants of spending decreases from biosimilars.
FDA Biosimilar Education Campaign Will Need To Be Targeted
Sen. Cassidy does not think additional appropriations are needed for a massive provider and patient education on biosimilars.